Successful engraftment of hematopoietic cells derived from AML or high-grade MDS-iPSC or using an approach similar to ours showed that the sequential introduction of mutations involved in AML (ASXL1, SRSF2, NRAS) allowed low burden in vivo engraftment, but without the capacity of serial transplantations (38). This evidence concerns the gene ASXL1 and myelodysplastic syndrome.